Literature DB >> 12034163

The current cost of heart failure to the National Health Service in the UK.

Simon Stewart1, Andrew Jenkins, Scot Buchan, Alistair McGuire, Simon Capewell, John J J V McMurray.   

Abstract

We have recently shown that heart failure admission rates continue to increase in the UK -- particularly in older age groups. As hospital activity represents the major cost component of health care expenditure related to heart failure, this study evaluated the current cost of this syndrome to the National Health Service (NHS) in the UK. We applied contemporary estimates of health care activity associated with heart failure to the whole UK population on an age and sex-specific basis to calculate its cost to the NHS for the year 1995. Direct components of health care included in these estimates were hospital admissions associated with a principal diagnosis of heart failure, associated outpatient consultations, general practice consultations and prescribed drug therapy. We also calculated the cost of nursing-home care following a primary heart failure admission and the cost of hospitalisations associated with a secondary diagnosis of heart failure. Adjusting for probable increases in hospital activity and the progressive ageing of the UK population, we have also projected the cost of heart failure to the NHS for the year 2000. We estimated that there were 988000 individuals requiring treatment for heart failure in the UK during 1995. The 'direct' cost of health care for these patients was estimated to be pound 716 million, or 1.83% of total NHS expenditure. Hospitalisations and drug prescriptions accounted for 69 and 18% of this expenditure, respectively. The additional costs associated with long-term nursing home care and secondary heart failure admissions accounted for a further pound 751 million (2.0% of total NHS expenditure). By the year 2000, we estimated that the combined total direct cost of heart failure would have risen to pound 905 million -- equivalent to 1.91% of total NHS expenditure. Using well-validated sets of data, these findings re-confirm the importance of heart failure as a major public health problem in the UK. The annual direct cost of heart failure to the NHS in 2000 is likely to be of the order of 1.9% of total expenditure -- the predominant cost component being hospitalisation.

Entities:  

Mesh:

Year:  2002        PMID: 12034163     DOI: 10.1016/s1388-9842(01)00198-2

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  125 in total

1.  Palliative care for heart failure.

Authors:  Simon Stewart; John J V McMurray
Journal:  BMJ       Date:  2002-10-26

Review 2.  Screening for left ventricular dysfunction in the community: role of hand held echocardiography and brain natriuretic peptides.

Authors:  R Senior; G Galasko; J V McMurray; J Mayet
Journal:  Heart       Date:  2003-11       Impact factor: 5.994

3.  Long term prognosis of heart failure after acute coronary syndromes without ST elevation.

Authors:  M C Shibata; J Collinson; A K Taneja; A Bakhai; M D Flather
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

Review 4.  Role of resynchronisation therapy and implantable cardioverter defibrillators in heart failure.

Authors:  S Ellery; L Williams; M Frenneaux
Journal:  Postgrad Med J       Date:  2006-01       Impact factor: 2.401

Review 5.  Assessing the diagnostic test accuracy of natriuretic peptides and ECG in the diagnosis of left ventricular systolic dysfunction: a systematic review and meta-analysis.

Authors:  Clare Davenport; Elaine Yee Lan Cheng; Yip Tung Tony Kwok; Annie Hiu On Lai; Taka Wakabayashi; Chris Hyde; Martin Connock
Journal:  Br J Gen Pract       Date:  2006-01       Impact factor: 5.386

6.  The impact of age on clinical outcomes following cardiac resynchronisation therapy.

Authors:  K Guha; D Konstantinou; L Mantziari; B N Modi; B Chandrasekaran; Z Khalique; T McDonagh; R Sharma
Journal:  J Interv Card Electrophysiol       Date:  2013-11-29       Impact factor: 1.900

7.  The impact of disease severity on EQ-5D and SF-6D utility discrepancies in chronic heart failure.

Authors:  Nick Kontodimopoulos; Michalis Argiriou; Nikolaos Theakos; Dimitris Niakas
Journal:  Eur J Health Econ       Date:  2010-05-15

Review 8.  Assessing the need for nuclear cardiology and other advanced cardiac imaging modalities in the developing world.

Authors:  João V Vitola; Leslee J Shaw; Adel H Allam; Pilar Orellana; Amalia Peix; Annare Ellmann; Kevin C Allman; B N Lee; Chanika Siritara; Felix Y J Keng; Gianmario Sambuceti; Marla C Kiess; Raffaele Giubbini; Salaheddine E Bouyoucef; Zuo-Xiang He; Gregory S Thomas; Fernando Mut; Maurizio Dondi
Journal:  J Nucl Cardiol       Date:  2009-07-22       Impact factor: 5.952

9.  Prospective evaluation and long-term follow-up of patients referred to secondary care based upon natriuretic peptide levels in primary care.

Authors:  John Gierula; Richard M Cubbon; Maria F Paton; Rowenna Byrom; Judith E Lowry; Sarah F Winsor; Melanie McGinlay; Emma Sunley; Emma Pickles; Lorraine C Kearney; Aaron Koshy; Thomas A Slater; Hemant K Chumun; Haqeel A Jamil; Kristian M Bailey; Julian H Barth; Mark T Kearney; Klaus K Witte
Journal:  Eur Heart J Qual Care Clin Outcomes       Date:  2019-07-01

10.  Innovative telemonitoring system for cardiology: from science to routine operation.

Authors:  P Kastner; J Morak; R Modre; A Kollmann; C Ebner; Fm Fruhwald; G Schreier
Journal:  Appl Clin Inform       Date:  2010-06-16       Impact factor: 2.342

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.